Skip to main content
Vivo Bio tech Ltd. logo

Vivo Bio tech Ltd. — Investor Relations & Filings

Ticker · 511509 ISIN · INE380K01017 LEI · 98450079E4M2CR80D882 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 440 across all filing types
Latest filing 2025-04-08 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS 511509

About Vivo Bio tech Ltd.

http://www.vivobio.com/

Vivo Bio Tech Ltd. is a preclinical Contract Research Organization (CRO) providing comprehensive drug discovery and development services. The company specializes in conducting in vivo preclinical studies, including toxicology, pharmacology, and pharmacokinetic evaluations. It operates advanced facilities for the breeding and distribution of Specific Pathogen Free (SPF) laboratory animal models, maintained through strategic partnerships with global leaders like Taconic Biosciences. Vivo Bio Tech offers regulatory-compliant services such as safety assessment, efficacy testing, and specialized research models to support pharmaceutical and biotechnology sectors. Its operations are characterized by adherence to Good Laboratory Practice (GLP) standards and AAALAC accreditation, ensuring high-quality data for global regulatory submissions.

Recent filings

Filing Released Lang Actions
The company has allotted 3,11,111 equity shares of Rs. 10/- each at an issue price of Rs. 45/- (premium of Rs. 35/- on each equity share) on conversion of warrants issued on preferential basis.
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification addressed to the stock exchange (BSE Limited) regarding the allotment of equity shares upon conversion of warrants issued on a preferential basis. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content details the number of shares allotted, the issue price, and the resulting increase in the company's share capital. The document is short (1532 characters) and serves as an announcement of a capital change event rather than a full financial report or detailed filing. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2025-04-08 English
Company has allotted 2,96,296 equity shares of Rs. 10/- each at an issue price of Rs.45/- (premium of Rs.35/- on each equity share) on conversion of warrants issued on preferential basis.
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification addressed to the stock exchange (BSE Limited) regarding the allotment of equity shares upon conversion of warrants issued on a preferential basis. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content details the number of shares allotted, the issue price, and the resulting increase in the company's share capital. There is no financial statement, management discussion, or detailed report content. The document is an announcement about a capital change event (share allotment). Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short (1532 characters), consistent with an announcement rather than a full report.
2025-03-29 English
Closure of Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange about the closure of the trading window pursuant to SEBI regulations and the company's internal code. It mentions the trading window closure period related to the upcoming declaration of audited financial results for the fiscal year ending March 31, 2025. The document does not contain any financial data, detailed report, or results itself. It is an announcement related to insider trading restrictions ahead of financial results disclosure. The length is only 1193 characters, indicating it is a brief notice rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance notices that do not fit other categories.
2025-03-27 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Antique Infotech Pvt Ltd
Major Shareholding Notification Classification · 95% confidence The document is a formal communication addressed to BSE Ltd and Vivo Bio Tech Limited, reporting under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the acquisition of 2,600,000 Convertible Equity Warrants on a preferential basis by Antique Infotech Private Limited in Vivo Bio Tech Limited. The content includes specifics about shareholding percentages before and after acquisition, mode of acquisition, dates, and share capital details. This matches the description of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels as per regulatory requirements. The document is not a full financial report, earnings release, or management discussion, nor is it an announcement of a report publication. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length and detail support a high confidence score.
2025-03-08 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kompella Ramakrishna Paramahamsa
Regulatory Filings
2025-03-07 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kompella Modini
Regulatory Filings
2025-03-07 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.